This is a preview of subscription content, log in via an institution to check access.
Notes
AstraZeneca BV funded the salaries of two of the study authors.
Reference
Van der Linden N, et al. The cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands. Diabetic Medicine : 3 Aug 2020. Available from: URL: http://doi.org/10.1111/dme.14371
Rights and permissions
About this article
Cite this article
Dapagliflozin cost-saving alternative to DPP-4 inhibitors in T2DM. PharmacoEcon Outcomes News 860, 17 (2020). https://doi.org/10.1007/s40274-020-7063-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7063-3